Effects of nivolumab alone or combination with molecular targeting agents for recurrent and refractory endometrial cancers with biomarker analyses.
2019
e17124Background: The
immunotherapydrug,
nivolumab, is now approved for several metastatic cancers, and has resulted in responses previously not seen with these cancers. Molecular targeting agents...
Keywords:
-
Correction
-
Source
-
Cite
-
Save
0
References
0
Citations
NaN
KQI